Latest close: a new 52-week lowSep 8, 2026what changed →
On our screens:Stocks with no debtCheap stocks by free cash flow yieldQuality compoundersQuality at a reasonable price
The financials
ANI Pharmaceuticals, Inc. by the numbers
ANI Pharmaceuticals, Inc. (ANIP) reported revenue of $237M in Q1 2026 (quarter ended Mar 31, 2026), up 20% from the same quarter a year earlier. That came with a gross margin of 61% and net income of $29M (12% of revenue). For the full year FY2025, revenue was $883M (+44% year on year) and net income $78M. Its largest product in Jun 2026 was Total Sales Of Generics And Other at $101M, 39.4% of the disclosed total, just ahead of Sales Of Generic Pharmaceutical Products at 38.8%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $237M | $197M | +20% |
| Gross profit | $144M | $124M | +16% |
| Operating income | $39M | $26M | +48% |
| Net income | $29M | $16M | +88% |
| Diluted EPS | $1.28 | $0.69 | +86% |
| Product | Revenue | Share |
|---|---|---|
| Total Sales Of Generics And Other | $101M | 39% |
| Sales Of Generic Pharmaceutical Products | $99M | 39% |
| Sales Of ILUVIEN And YUTIQ | $19M | 7.3% |
| Sales Of Established Brand Royalties And Other | $18M | 6.9% |
| Sales Of Established Brands | $12M | 4.6% |
| Unapproved Products | $5.7M | 2.2% |
| Sales Of Generic Other | $1.6M | 0.6% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $255.3M (-8.1%)
Sales Of Generic Pharmaceutical Products grew +9.7% year on yearSales Of Generic Other -59% year on year
Segment Latestquarter on quarteryear on year
- Total Sales Of Generics And Other$100.7M$100.7MQoQ -7.8%year on year +6.8%-7.8%+6.8%
- Sales Of Generic Pharmaceutical Products$99.1M$99.1MQoQ -6.0%year on year +9.7%-6.0%+9.7%
- Sales Of ILUVIEN And YUTIQ$18.7M$18.7MQoQ -2.8%year on year -16%-2.8%-16%
- Sales Of Established Brand Royalties And Other$17.7M$17.7MQoQ -18%year on year --18%-
- Sales Of Established Brands$11.8M$11.8MQoQ -4.2%year on year -10%-4.2%-10%
- Unapproved Products$5.7M$5.7MQoQ -9.5%year on year -6.6%-9.5%-6.6%
- Sales Of Generic Other$1.6M$1.6MQoQ -58%year on year -59%-58%-59%
Drug Manufacturers - Specialty & Generic
Ranks #13 of 29 by Smart Score